Budget Impact Analysis of Impella CP^® Utilization in the Management of Cardiogenic Shock in France: A Health Economic Analysis.

ABSTRACT:

Introduction

Early detection and treatment of cardiogenic shock (CS) is crucial to avoid irreparable multiorgan damage and mortality. Impella CP^® is a novel temporary mechanical circulatory support (MCS) device associated with greater hemodynamic support and significantly fewer device-related complications compared with other MCS devices, e.g., intra-aortic balloon pumps (IABP) and venoarterial extracorporeal membrane oxygenation (VA-ECMO). The present study evaluated the budget impact of introducing Impella CP versus IABP and VA-ECMO in patients with CS following an acute myocardial infarction (MI) in France.

Methods

A budget impact model was developed to compare the cost of introducing Impella CP with continuing IABP and VA-ECMO treatment from a Mandatory Health

SUBMITTER: Delmas C 

PROVIDER: S-EPMC8918169 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature